| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,407,610 ) |
| | 2025 | 2025 | NEONC TECHNOLOGIES INC | 8335 W SUNSET BLVD | LOS ANGELES | CA | 90069-1500 | LOS ANGELES | USA | R41CA271879 | Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia | 000 | 1 | NIH | 8/6/2025 | $399,998 |
| | 2025 | 2025 | NEONC TECHNOLOGIES INC | 8335 W SUNSET BLVD | LOS ANGELES | CA | 90069-1500 | LOS ANGELES | USA | R42CA246902 | Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas | 000 | 2 | NIH | 9/23/2025 | $1,007,612 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | NEONC TECHNOLOGIES INC | 8335 W SUNSET BLVD | LOS ANGELES | CA | 90069-1500 | LOS ANGELES | USA | R41CA246902 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas | 000 | 1 | NIH | 10/20/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA246902 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas | 000 | 1 | NIH | 5/12/2021 | $0 |
| | 2021 | 2018 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1500 | LOS ANGELES | USA | R41CA217551 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | 000 | 1 | NIH | 10/14/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $336,000 ) |
| | 2020 | 2020 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA246902 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas | 000 | 1 | NIH | 3/25/2020 | $336,000 |
|
| Issue Date FY: 2019 ( Subtotal = $1,450 ) |
| | 2019 | 2019 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA217551 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | 001 | 1 | NIH | 8/6/2019 | $1,450 |
| | 2019 | 2018 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA217551 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | 000 | 1 | NIH | 5/3/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $300,000 ) |
| | 2018 | 2018 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA217551 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | 000 | 1 | NIH | 3/23/2018 | $300,000 |
| | 2018 | 2016 | NEONC TECHNOLOGIES, INC. | 8335 SUNSET BLVD STE 240 | LOS ANGELES | CA | 90069-1555 | LOS ANGELES | USA | R41CA192419 | Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors | 000 | 1 | NIH | 11/14/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $300,000 ) |
| | 2016 | 2016 | NEONC TECHNOLOGIES, INC | 1203 SWEETZER AVE #313 | WEST HOLLYWOOD | CA | 90069 | LOS ANGELES | USA | R41CA192419 | Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors | 000 | 1 | NIH | 6/20/2016 | $300,000 |
|
|
